203 related articles for article (PubMed ID: 30402602)
1. Risk factors in Hymenoptera venom allergy.
Ruëff F; Kroth J; Przybilla B
Allergol Select; 2017; 1(1):53-58. PubMed ID: 30402602
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) in collaboration with the Arbeitsgemeinschaft für Berufs- und Umweltdermatologie e.V. (ABD), the Medical Association of German Allergologists (AeDA), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNOKC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Allergy and Environmental Medicine (GPA), German Respiratory Society (DGP), and the Austrian Society for Allergy and Immunology (ÖGAI).
Ruëff F; Bauer A; Becker S; Brehler R; Brockow K; Chaker AM; Darsow U; Fischer J; Fuchs T; Gerstlauer M; Gernert S; Hamelmann E; Hötzenecker W; Klimek L; Lange L; Merk H; Mülleneisen NK; Neustädter I; Pfützner W; Sieber W; Sitter H; Skudlik C; Treudler R; Wedi B; Wöhrl S; Worm M; Jakob T
Allergol Select; 2023; 7():154-190. PubMed ID: 37854067
[TBL] [Abstract][Full Text] [Related]
3. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Seitz MJ; Aberer W; Bodzenta-Lukaszyk A; Bonifazi F; Campi P; Darsow U; Haeberli G; Hawranek T; Küchenhoff H; Lang R; Quercia O; Reider N; Schmid-Grendelmeier P; Severino M; Sturm GJ; Treudler R; Wüthrich B
PLoS One; 2013; 8(5):e63233. PubMed ID: 23700415
[TBL] [Abstract][Full Text] [Related]
5. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
6. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
7. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis.
Gülsen A; Ruëff F; Jappe U
Allergol Select; 2021; 5():128-132. PubMed ID: 33733040
[TBL] [Abstract][Full Text] [Related]
9. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of venom immunotherapy: Evaluation of 581 rush- and ultra-rush induction protocols (safety of rush and ultra-rush venom immunotherapy).
Stock R; Fischer T; Aẞmus K; Zoeller N; Ackermann H; Kaufmann R; Meissner M; Valesky E
World Allergy Organ J; 2021 Jan; 14(1):100496. PubMed ID: 33376576
[TBL] [Abstract][Full Text] [Related]
11. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
12. Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected.
Bonadonna P; Zanotti R; Pagani M; Bonifacio M; Scaffidi L; Olivieri E; Franchini M; Reccardini F; Costantino MT; Roncallo C; Mauro M; Boni E; Rizzini FL; Bilò MB; Marcarelli AR; Passalacqua G
J Allergy Clin Immunol Pract; 2018; 6(4):1368-1372. PubMed ID: 29258788
[TBL] [Abstract][Full Text] [Related]
13. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.
Haeberli G; Brönnimann M; Hunziker T; Müller U
Clin Exp Allergy; 2003 Sep; 33(9):1216-20. PubMed ID: 12956741
[TBL] [Abstract][Full Text] [Related]
14. Anaphylactic reactions in the build-up phase of rush immunotherapy for bee venom allergy in pediatric patients: a single-center experience.
Glaeser A; Müller C; Bode S
Clin Mol Allergy; 2022 Apr; 20(1):4. PubMed ID: 35488298
[TBL] [Abstract][Full Text] [Related]
15. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
16. Safety of 100 µg venom immunotherapy rush protocols in children compared to adults.
Stoevesandt J; Hosp C; Kerstan A; Trautmann A
Allergy Asthma Clin Immunol; 2017; 13():32. PubMed ID: 28706538
[TBL] [Abstract][Full Text] [Related]
17. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
18. Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy.
Korošec P; Žiberna K; Šilar M; Dežman M; Čelesnik Smodiš N; Rijavec M; Kopač P; Eržen R; Lalek N; Bajrović N; Košnik M; Zidarn M
Clin Exp Allergy; 2015 Oct; 45(10):1579-89. PubMed ID: 26046807
[TBL] [Abstract][Full Text] [Related]
19. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Körner M; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B
J Allergy Clin Immunol; 2009 Nov; 124(5):1047-54. PubMed ID: 19895993
[TBL] [Abstract][Full Text] [Related]
20. Rush Venom Immunotherapy in Children.
Confino-Cohen R; Rosman Y; Goldberg A
J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
